Literature DB >> 11841415

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

Mark A Crowther1, Leslie R Berry, Paul T Monagle, Anthony K C Chan.   

Abstract

Protamine is unable to completely reverse the anticoagulant effect of the low-molecular-weight heparins (LMWH), a fact of clinical importance given the rapid increase in use of LMWH in clinical practice. This investigation sought to determine the mechanism by which LMWH were able to resist protamine-mediated inactivation. Affinity fractionation of LMWH by passage through a protamine column, with subsequent determination of molecular mass and sulphate charge density, demonstrated that the protamine-resistant fraction in LMWH is an ultra-low-molecular-weight fraction with low sulphate charge density. This group of molecules was not found in unfractionated heparin, even when species of similar molecular mass were compared. We then determined that different commercially available LMWH varied in their ability to be neutralized by protamine, and that this variability correlated with the total sulphate content of the LMWH. We conclude that reduced sulphate charge, not molecular mass, is the principle reason that protamine is unable to fully inactivate LMWH. Furthermore, different LMWH vary in their ability to be neutralized by protamine, suggesting that product-specific recommendations for neutralization might be developed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841415     DOI: 10.1046/j.1365-2141.2002.03233.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

1.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  [Jugular vein thrombosis caused by hypercoagulability following in-vitro fertilization-activated protein C resistance and immobilization].

Authors:  K Stölzel; S Jovanovic; A E Albers
Journal:  HNO       Date:  2013-03       Impact factor: 1.284

Review 4.  New anticoagulants: how to deal with treatment failure and bleeding complications.

Authors:  Rashid S Kazmi; Bashir A Lwaleed
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 5.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

6.  Inadvertent Overdose of Low-Molecular-Weight Heparin in an Elderly Patient with Deep Vein Thrombosis and Acute Kidney Injury.

Authors:  Abdullah S Al Saleh; David Anderson
Journal:  Can J Hosp Pharm       Date:  2016-08-31

7.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Authors:  Genmin Lu; Francis R DeGuzman; Stanley J Hollenbach; Mark J Karbarz; Keith Abe; Gail Lee; Peng Luan; Athiwat Hutchaleelaha; Mayuko Inagaki; Pamela B Conley; David R Phillips; Uma Sinha
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

Review 8.  [Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].

Authors:  M Lancé; B Stessel; K Hamulyák; M A Marcus
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

Review 9.  Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Authors:  Shailja V Parikh; Ellen C Keeley
Journal:  Vasc Health Risk Manag       Date:  2009-08-20

10.  Prevention and treatment of venous thromboembolism in the elderly patient.

Authors:  Enrico Tincani; Mark A Crowther; Fabrizio Turrini; Domenico Prisco
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.